Citigroup
MRTX

Citigroup’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Citigroup’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-25,000
Closed -$1.13M – 5965
2022
Q4 		$1.13M Buy
+25,000
New +$1.62M ﹤0.01% 2503
2022
Q3 		– Sell
-15,000
Closed -$1.01M – 6484
2022
Q2 		$1.01M Buy
+15,000
New +$954K ﹤0.01% 2634
2020
Q3 		– Sell
-600
Closed -$69K – 7642
2020
Q2 		$69K Sell
600
-400
-40% -$38.8K ﹤0.01% 5836
2020
Q1 		$77K Buy
1,000
+300
+43% +$26.9K ﹤0.01% 5583
2019
Q4 		$90K Buy
700
+600
+600% +$57.9K ﹤0.01% 5857
2019
Q3 		$8K Sell
100
-5,600
-98% -$526K ﹤0.01% 7186
2019
Q2 		$587K Buy
5,700
+3,300
+138% +$257K ﹤0.01% 4253
2019
Q1 		$176K Sell
2,400
-600
-20% -$40.8K ﹤0.01% 5225
2018
Q4 		$127K Buy
3,000
+1,200
+67% +$47.8K ﹤0.01% 5454
2018
Q3 		$85K Buy
+1,800
New +$100K ﹤0.01% 6054

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Citigroup's MRTX Position: Q1 2024 in Review

Citigroup sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 61,961 shares — an estimated $3.64M sold.

Citigroup first reported a position in MRTX in Q1 2014 and held it in 39 quarters. The position peaked at $15.3M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Citigroup reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Citigroup sold 61,961 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $3.64M.
  • Citigroup first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2014 and held it in 39 quarters.
  • Citigroup's Mirati Therapeutics, Inc. Common Stock position peaked at $15.3M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Citigroup's 13F filing for Q1 2024, filed 10 May 2024.